If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
590.00    2.00 (0.34%)
Bid:
586.00
Ask:
588.00
Spread: 2.00 (0.341%)
Market Cap: £514.04m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

US FDA approval: Total Knee Study

17 Sep 2024 14:00

RNS Number : 5569E
Victrex PLC
17 September 2024
 

17 September 2024

Victrex plc

US FDA Approval for Total Knee Arthroplasty Study in the US

Victrex plc is an innovative world leader in high performance polymer solutions, delivering sustainable products which support CO2 reduction and enable environmental and societal benefit in multiple end-markets.

The Group today announces that, in partnership with Maxx Orthopedics Inc, the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for Freedom® Total Knee System with Invibio PEEK-OPTIMA™ Femoral Component, as a staged study. The study, projected to be 120 patients at clinical sites in the US, will compare using the PEEK-OPTIMA™ Femoral Knee Component to a controlled registry of the same system using traditional metal femoral components.

 

The US study will build on the existing clinical trial for PEEK Knee at sites in Belgium, India and Italy, which has been progressing strongly since the first implant in 2021, with no clinical intervention. A regulatory submission in India is also expected imminently, supporting the potential for a commercial PEEK Knee in the market in 2025.

 

Jakob Sigurdsson, Chief Executive of Victrex, said: "PEEK Knee has the potential to be a game-changer for total knee replacement. Being able to further assess its benefits through rigorous clinical evaluation in the US will build on the strong progress so far through clinical trial sites in Europe and India. We look forward to the study's progression and remain optimistic about the transformative impact this pioneering device could have on the future of joint replacement.

 

"In relation to the regulatory submission in India, following a tenacious focus on innovation, development and investment to scale this significant opportunity, we now look forward to the potential for a PEEK Knee being in the market during 2025 and commercial revenues. We also continue to see growing interest in PEEK Knee from across the medical device industry, beyond our existing collaborations."

 

Victrex plc:

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG

+44 (0) 7809 595831

Jakob Sigurdsson, Chief Executive

+44 (0) 1253 897700

Ian Melling, Chief Financial Officer 

+44 (0) 1253 897700

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, enable environmental and societal benefit for our customers and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFVFARIDLIS
Date   Source Headline
19th Mar 20154:32 pmRNSHolding(s) in Company
17th Mar 20152:28 pmRNSDirector/PDMR Shareholding
5th Mar 20157:00 amRNSAdditional Listing
27th Feb 201510:00 amRNSTotal Voting Rights
26th Feb 20154:53 pmRNSHolding(s) in Company
25th Feb 20154:43 pmRNSHolding(s) in Company
19th Feb 20153:03 pmRNSDirector/PDMR Shareholding
17th Feb 20152:25 pmRNSDirector/PDMR Shareholding
4th Feb 20153:59 pmRNSResult of AGM
4th Feb 20157:00 amRNSAGM and Q1 Interim Management Statement
30th Jan 20152:00 pmRNSTotal Voting Rights
26th Jan 201512:03 pmRNSDirector Declaration
19th Jan 20153:38 pmRNSDirector/PDMR Shareholding
14th Jan 20154:00 pmRNSHolding(s) in Company
5th Jan 201511:43 amRNSAnnual Financial Report
31st Dec 20147:00 amRNSTotal Voting Rights
19th Dec 20147:00 amRNSDirector Declaration
18th Dec 20148:34 amRNSDirectorate Change
18th Dec 20147:00 amRNSDirectorate Change
17th Dec 201412:45 pmRNSDirector/PDMR Shareholding
16th Dec 20145:13 pmRNSDirector/PDMR Shareholding
16th Dec 20144:43 pmRNSDirector/PDMR Shareholding
9th Dec 20147:00 amRNSFinal Results
1st Dec 20141:51 pmRNSBlocklisting Interim Review
28th Nov 201410:00 amRNSTotal Voting Rights
25th Nov 20144:30 pmRNSHolding(s) in Company
18th Nov 201411:38 amRNSDirector/PDMR Shareholding
6th Nov 201411:12 amRNSDirector Declaration
31st Oct 20149:27 amRNSTotal Voting Rights
21st Oct 20143:14 pmRNSSenior Independent Director Appointment
20th Oct 20144:38 pmRNSHolding(s) in Company
20th Oct 20149:05 amRNSDirector/PDMR Shareholding
9th Oct 20147:00 amRNSTrading Statement
1st Oct 20143:56 pmRNSDirector Disclosure Section 430 (2B)
1st Oct 20147:00 amRNSDirectorate Change
30th Sep 20141:34 pmRNSTotal Voting Rights
24th Sep 20144:12 pmRNSHolding(s) in Company
17th Sep 20141:16 pmRNSDirector/PDMR Shareholding
29th Aug 201410:00 amRNSTotal Voting Rights
19th Aug 20142:34 pmRNSDirector/PDMR Shareholding
31st Jul 20149:37 amRNSTotal Voting Rights
30th Jul 20147:00 amRNSInterim Management Statement
21st Jul 20142:13 pmRNSHolding(s) in Company
30th Jun 20142:54 pmRNSTotal Voting Rights
27th Jun 20144:00 pmRNSHolding(s) in Company
23rd Jun 201411:07 amRNSHolding(s) in Company
17th Jun 20144:04 pmRNSDirector/PDMR Shareholding
9th Jun 201411:18 amRNSBlocklisting Interim Review
4th Jun 20142:28 pmRNSDirector/PDMR Shareholding
30th May 201412:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.